

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation, East Hanover, NJ 07927

Novartis Pharmaceuticals Corporation

This document contains confidential and potentially commercially sensitive information.

If you are not a named recipient, please do not disseminate, distribute or copy this e-mail. If you have received this e-mail by mistake, please notify the sender immediately by e-mail and delete this e-mail from your system.

The following information is confidential and is intended only for the individual(s) named.

If you are not a named recipient, please do not disseminate, distribute or copy this e-mail. If you have received this e-mail by mistake, please notify the sender immediately by e-mail and delete this e-mail from your system.

©1990-2008 Novartis

Novartis

8) W. Dumouchel, D. Fram, X. Yang : Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004). Annals of Clinical Psychiatry, 20(1), 21-31, 2008.

9) K. Hedenmalm, S. Hagg, M. Stahl, O. Mortimer, O. Spigset : Glucose intolerance with atypical antipsychotics. Drug Safety, 25(15), 1107-16, 2002.

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

	Novartis ^{a)}	Novartis	Novartis (%)
Novartis	77	4	5.19
Novartis	77	2	2.60
Novartis	77	1	1.30
Novartis	77	1	1.30
Novartis	77	0	0

a) Novartis 1301, 1201, 1202, 1203

Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation 1990-2008

□□□ ^{b)}	363	69	3	50	44	4	32	150	11
	□19.0□	□0.8□	□13.8□	□12.1□	□1.1□	□8.8□	□41.3□	□3.0□	

a) □□□□□□□□□□□□□□□□

b) □□□□□□□□

□□□□□□□□□□□□□□□□

□□□□□□

Source URL: <https://www.pro.novartis.com/jp-ja/products/clozaril/clinical/12>